Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 29, 2018 | May 30, 2018 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · Executive Chairman | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 270,198 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Purchase · Acquired 5,000 · Balance 270,198 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,644 |
Last balance in matching sequence
After 2026-05-11 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-05-11 · Conversion · Acquired 28,698 · Balance 28,698 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 3 · 2026-05-11 · Exercise / conversion · Acquired 2,963 · Balance 31,661 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 4 · 2026-05-11 · Tax withholding · Disposed 17 · Balance 31,644 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Conversion · Disposed 79,166 · Balance 0 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Conversion · Disposed 96,002 · Balance 0 F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 626,220 |
Reported balance
After 2026-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-07 · Grant · Acquired 626,220 · Balance 626,220 F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
| Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Exercise / conversion · Disposed 28,800 · Balance 0 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.
F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
QUEST DIAGNOSTICS INC
Report date May 29, 2018 · Filed May 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2018-05-29 transaction · row 1
1 source rowRow 1 · 2018-05-29 · Sale · Disposed 1,644 · Balance 6,000 |
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | IndirectBy Racing Beach Ventures LLC | 7,500 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,500 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,797 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 3,547 · Balance 34,797 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 440 |
Reported balance
Holding disclosure · report date 2026-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 440 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date March 24, 2006 · Filed March 28, 2006
Section 16 reporting ended · disclosed 2006-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 209,401 |
Ending reported balance
After 2006-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2006-03-24 · Tax withholding · Disposed 91,846 · Balance 309,401 Row 2 · 2006-03-24 · Disposition to issuer · Disposed 100,000 · Balance 209,401 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 635 |
Reported balance
Holding disclosure · report date 2006-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 635 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2014 Filed Oct 1, 2014 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 79,817 | $112.21 | $8,956,265.57 |
DisclosureSEC source: 0001209191-14-060604 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,446 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.21 (range $111.61 to $112.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 24,729 | $111.31 | $2,752,584.99 |
DisclosureSEC source: 0001209191-14-060604 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,263 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.31 (range $110.61 to $111.60). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 200,000 | $29.98 | $5,996,000.00 |
DisclosureSEC source: 0001209191-14-060604 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2014 Filed Jul 17, 2014 22:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 106,500 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-14-047901 · doc4.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,500 Underlying: Common Stock · 106,500 shares Expires 2024-07-14 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| May 07, 2014 Filed May 9, 2014 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 66,689 | $0.01 | $666.89 |
DisclosureSEC source: 0001209191-14-032599 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,792 F1 · kind: These restricted shares did not vest in accordance with the terms of the award and were repurchased by the company on May 7, 2014 at the original issue price. Read SEC document |
| February 07, 2014 Filed Feb 11, 2014 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 35,944 | $80.00 | $2,875,520.00 |
DisclosureSEC source: 0001209191-14-009094 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,481 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 213,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008355 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 64,500 | $0.01 | $645.00 |
DisclosureSEC source: 0001209191-14-008355 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,425 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| January 16, 2014 Filed Jan 17, 2014 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 45,000 | $0.00 Strike: $29.98 | $0.00 |
DisclosureSEC source: 0001209191-14-003733 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,108 Underlying: Common Stock · 45,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 12/14/2011. Read SEC document |
| January 16, 2014 Filed Jan 17, 2014 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 45,000 | $80.00 | $3,600,000.00 |
DisclosureSEC source: 0001209191-14-003733 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,925 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| January 16, 2014 Filed Jan 17, 2014 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 45,000 | $29.98 | $1,349,100.00 |
DisclosureSEC source: 0001209191-14-003733 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2013 Filed Dec 12, 2013 22:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,834 | $65.48 | $643,930.32 |
DisclosureSEC source: 0001209191-13-056697 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,925 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $65.48 (range $65.05 to $65.92). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 106,500 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038685 · doc4.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,500 Underlying: Common Stock · 106,500 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| February 06, 2013 Filed Feb 7, 2013 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 33,345 | $45.83 | $1,528,201.35 |
DisclosureSEC source: 0001209191-13-007122 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,371 F2 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, established to sell a portion of shares upon vesting to cover tax laibilities. F3 · price: Open market sales reported on this line occurred at a weighted average price of $45.83 (range $45.57 to $46.08). F4 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 177,000 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007122 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires 2023-02-04 F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 39,334 | $0.01 | $393.34 |
DisclosureSEC source: 0001209191-13-007122 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,716 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| July 25, 2012 Filed Jul 26, 2012 20:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee StockOption (right to buy) · Derivative | 118,000 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-12-039156 · doc4.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 10/25/2012. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 458,108 | $0.00 Strike: $29.99 | $0.00 |
DisclosureSEC source: 0001209191-11-061776 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO Designate 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,108 Underlying: Common Stock · 458,108 shares Expires 2021-12-13 F3 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 12/14/2011. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 133,378 | $0.01 | $1,333.78 |
DisclosureSEC source: 0001209191-11-061776 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO Designate 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,995 F2 · shares: Performance-based stock grant under 2006 Stock and Option Plan that will vest only if Vertex meets certain performance objectives. Up to 50% of the grant will vest on the date of the Company's first regularly scheduled board meeting in 2013 and up to 50% of the grant will vest on the date of the Company's 2014 Annual Meeting of its shareholders. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 50,017 | $0.01 | $500.17 |
DisclosureSEC source: 0001209191-11-061776 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO Designate 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,617 F1 · shares: Stock grant under 2006 Stock and Option Plan vesting on December 14, 2014. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-11-032539 · doc4.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2021-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 15, 2010 Filed Dec 17, 2010 14:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 1,527 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000875320-10-000060 · edgar.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,527 Underlying: Common Stock · 1,527 shares Expires 2020-12-14 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000033 · edgar.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 04, 2010 Filed May 5, 2010 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 1,300 | $38.40 | $49,920.00 |
DisclosureSEC source: 0000875320-10-000020 · edgar.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Read SEC document |
| April 23, 2010 Filed Apr 26, 2010 14:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 1,300 | $38.60 | $50,180.00 |
DisclosureSEC source: 0000875320-10-000019 · edgar.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Read SEC document |
| July 06, 2009 Filed Jul 7, 2009 20:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0000875320-09-000056 · edgar.xml · derivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-07-05 F1 · shares: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| March 24, 2006 Filed Mar 28, 2006 16:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Disposition to issuerCommon shares without par value | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-019735 · a4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,401 Read SEC document |
| March 24, 2006 Filed Mar 28, 2006 16:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 91,846 | $43.68 | $4,011,833.28 |
DisclosureSEC source: 0001104659-06-019735 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,401 Read SEC document |
| February 18, 2006 Filed Feb 22, 2006 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,102 | $44.15 | $269,403.30 |
DisclosureSEC source: 0001104659-06-011235 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,247 Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 310,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001104659-06-011235 · a4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common shares · 310,000 shares Expires 2016-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 103,334 on 02/17/2007, 103,333 on 02/17/2008 and 103,333 on 02/17/2009. Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $44.41 | $88,820.00 |
DisclosureSEC source: 0001104659-06-011235 · a4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,247 Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 100,000 | $44.16 | $4,416,000.00 |
DisclosureSEC source: 0001104659-06-011235 · a4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,247 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 70,249 | $0.00 Strike: $42.94 | $0.00 |
DisclosureSEC source: 0001104659-06-005671 · a4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,249 Underlying: common shares · 70,249 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 83,544 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-06-005671 · a4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,877 Underlying: common shares · 83,544 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 70,249 | $42.94 | $3,016,492.06 |
DisclosureSEC source: 0001104659-06-005671 · a4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,349 Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 83,544 | $33.23 | $2,776,284.08 |
DisclosureSEC source: 0001104659-06-005671 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2005 Filed Jul 6, 2005 20:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 31,923 | $49.31 | $1,573,963.52 |
DisclosureSEC source: 0001104659-05-031355 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,054 Read SEC document |
| June 07, 2005 Filed Jun 9, 2005 19:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 19,944 | $0.00 Strike: $48.45 | $0.00 |
DisclosureSEC source: 0001104659-05-027522 · a4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,944 Underlying: common shares · 19,944 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| June 07, 2005 Filed Jun 9, 2005 19:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 24,629 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-05-027522 · a4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,421 Underlying: common shares · 24,629 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| June 07, 2005 Filed Jun 9, 2005 19:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 19,944 | $48.45 | $966,286.80 |
DisclosureSEC source: 0001104659-05-027522 · a4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,977 Read SEC document |
| June 07, 2005 Filed Jun 9, 2005 19:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 24,629 | $33.23 | $818,456.15 |
DisclosureSEC source: 0001104659-05-027522 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2005 Filed Feb 23, 2005 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 313,200 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001104659-05-008009 · a4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,200 Underlying: common shares · 313,200 shares Expires 2015-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 104,400 on 2/18/06, 104,400 on 2/18/07 and 104,400 on 2/18/08. Read SEC document |
| February 18, 2005 Filed Feb 23, 2005 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 46,400 | $46.34 | $2,150,176.00 |
DisclosureSEC source: 0001104659-05-008009 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,292 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| September 01, 2004 Filed Sep 2, 2004 19:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 13,569 | $0.00 Strike: $41.69 | $0.00 |
DisclosureSEC source: 0001104659-04-026738 · a4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,569 Underlying: common shares · 13,569 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| September 01, 2004 Filed Sep 2, 2004 19:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 15,469 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-04-026738 · a4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,050 Underlying: common shares · 15,469 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| September 01, 2004 Filed Sep 2, 2004 19:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,569 | $41.69 | $565,691.61 |
DisclosureSEC source: 0001104659-04-026738 · a4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,892 Read SEC document |
| September 01, 2004 Filed Sep 2, 2004 19:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 15,469 | $33.23 | $514,056.53 |
DisclosureSEC source: 0001104659-04-026738 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 270,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005609 · a4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: common shares · 270,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16b under Rule 16b-3. The option becomes exercisable in annual increments of 1/3, 1/3, and 1/3 beginning on February 20, 2005, the first anniversary date of the grant. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 40,000 | $43.66 | $1,746,400.00 |
DisclosureSEC source: 0001104659-04-005609 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,992 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16b under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 11,800 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0001104659-04-005014 · a4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: common shares · 11,800 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.